Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Teva appears to be a company with strong revenue and acceptable gross profitability, but with a noticeable discount in earnings quality and balance sheet resilience. Revenue remains large and stable, and gross margin is holding around 52%, which is decent for pharmaceuticals and suggests pricing power in the portfolio. At the same time, operating margin and net profit margin are noticeably below industry benchmarks, and in the latest TTM net income and operating income have effectively dropped to zero, which weakens the quality of the current valuation. The multiples look mixed: P/S is below the industry median, but P/E, P/B, and P/FCF are materially higher, which usually indicates an expensive valuation relative to earnings, equity, and free cash flow. The debt burden remains elevated: debt/equity is significantly above the median, long-term debt is large, and current and quick ratios are below comfortable levels, so the financial profile cannot be called low-risk. The positive side is a solid amount of cash on hand and a meaningful level of shareholders’ equity, which partially offsets the debt pressure. ROE looks acceptable, but ROA and ROI are weak, and return on tangible equity remains at zero, indicating low efficiency in the use of assets and capital. Year-by-year trends show improvement in several balance sheet metrics and a reduction in debt, but operating profitability remains volatile and does not show a sustainable upward trend. Dividend yield is low and does not appear to be a sufficient factor to justify a higher valuation for the stock. Overall, the fundamentals support a moderately cautious view: the business is large-scale and does not look problematic at the revenue level, but earnings quality, liquidity, and leverage limit the potential for a meaningful increase in the target valuation. Therefore, the target forecast adjustment should be modest and downward, reflecting weaker profitability and expensive multiples amid continuing balance sheet risks.

Teva Pharmaceutical Industries Limited

Сильный индекс, значительно вырос. Быки резко укрепили уверенность в своих позициях.

Strong index, significantly up. Bulls sharply strengthened confidence in their positions.

Сильный индекс, незначительно упал. Медведи в растерянности.

Strong index, slightly down. The bears are confused.

Средний индекс, значительно вырос. Рынок на стороне быков.

Medium index, significantly up. The market is on the bulls' side.

Слабый индекс, значительно упал. Рынок не поддерживает медведей.

Weak index, significantly down. The market does not support the bears.

Сильный индекс, значительно упал. Отток средств из лонгов резко увеличился и находится на высоком уровне.

Strong index, significantly down. The outflow of funds from longs has increased sharply and is at a high level.

Сильный индекс, значительно упал

Teva’s strong revenue and gross margin are offset by weak liquidity, high debt burden, and an expensive valuation based on earnings and FCF.

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI EAFE ETF (Symbol: IEFA) where we have detected an approximate $808.6 million dollar inflow -- that's a 0.4% increase week over week in outstanding units (from 1,942,200,000 to 1,950,200,000). Among the largest underlying components of IEFA, in trading today Spotify Technology SA (Symbol: SPOT) is down about 2.1%, Sea Ltd (Symbol: SE) is up about 0.1%, and Teva Pharmaceutical Industries Ltd (Symbol: TEVA) is lower by about 0.1%. For a complete list of holdings, visit the IEFA Holdings page » The chart below shows the one year price performance of IEFA, versus its 200 day moving average:
Looking at the chart above, IEFA's low point in its 52 week range is $85.025 per share, with $101.44 as the 52 week high point — that compares with a last trade of $100.72. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Further IEFA Research:

IEFA, SPOT, SE, TEVA: ETF Inflow Alert

(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), a biopharmaceutical company, announced its intentions to issue senior notes through its special-purpose finance subsidiaries.
Teva Pharmaceutical Finance Netherlands II B.V. (Teva Finance II) intends to issue euro-denominated senior notes, while Teva Pharmaceutical Finance Netherlands III B.V. (Teva Finance III) and Teva Pharmaceutical Finance Netherlands IV B.V. (Teva Finance IV) intend to issue U.S. dollar-denominated senior notes. The offering is subject to market conditions.
The notes will be unsecured senior obligations of the issuing subsidiaries and will be unconditionally guaranteed on a senior basis by Teva.
Teva did not disclose the expected net proceeds from the offering. The company expects to use the net proceeds, together with cash on hand, to fund the redemption of certain outstanding notes, pay related fees and expenses, and for general corporate purposes, including debt repayment, through tender offers or earlier redemption.
The planned redemptions include all outstanding 6.750% senior notes due 2028, as well as the 7.875% and 7.375% sustainability-linked senior notes due 2029.
Additionally, Teva intends to redeem up to $450 million of 4.750% sustainability-linked senior notes due 2027, and up to €1.25 billions of 4.375% sustainability-linked senior notes due 2030.
The conditional redemptions are expected to depend on completion of the notes offering, while the offering itself is not conditioned on the redemptions. Teva may also modify the redemption amounts or redeem additional outstanding notes at its discretion.
As of June 30, 2026, cash and cash equivalents amounted to $3,655 million.
Teva shares have traded between $18.21 and $38.37 over the last year.
TEVA closed Friday's (04.09.2026) trade at $36.36, down 0.71%. In the after-hours trading on Friday, shares were up 2.28% at $37.19.

Teva Launches Senior Notes Offering To Refinance Existing Debt

The NASDAQ 100 After Hours Indicator is down -45.18 to 29,498.97. The total After hours volume is currently 112,199,562 shares traded.
The following are the most active stocks for the after hours session:
NIO Inc. (NIO) is +0.0015 at $3.80, with 7,386,156 shares traded. NIO's current last sale is 59.4% of the target price of $6.4.
Intel Corporation (INTC) is -0.19 at $95.61, with 4,907,016 shares traded. INTC's current last sale is 86.14% of the target price of $111.
Teva Pharmaceutical Industries Limited (TEVA) is unchanged at $36.36, with 4,896,424 shares traded. As reported by Zacks, the current mean recommendation for TEVA is in the "buy range".
Amazon.com, Inc. (AMZN) is -0.4853 at $258.02, with 3,419,005 shares traded. As reported by Zacks, the current mean recommendation for AMZN is in the "buy range".
Ford Motor Company (F) is -0.03 at $14.59, with 3,337,380 shares traded. F's current last sale is 97.27% of the target price of $15.
NVIDIA Corporation (NVDA) is -0.5 at $229.86, with 3,252,616 shares traded. Over the last four weeks they have had 10 up revisions for the earnings forecast, for the fiscal quarter ending Oct 2026. The consensus EPS forecast is $2.47. As reported by Zacks, the current mean recommendation for NVDA is in the "buy range".
ExxonMobil Holdings Corporation (XOM) is unchanged at $159.47, with 3,141,002 shares traded. XOM's current last sale is 93.81% of the target price of $170.
Coca-Cola Company (The) (KO) is +0.07 at $88.14, with 3,027,325 shares traded. As reported by Zacks, the current mean recommendation for KO is in the "buy range".
CNH Industrial N.V. (CNH) is -0.01 at $14.39, with 2,705,790 shares traded., following a 52-week high recorded in today's regular session.
Arbutus Biopharma Corporation (ABUS) is +0.01 at $5.16, with 2,680,748 shares traded. As reported in the last short interest update the days to cover for ABUS is 15.101523; this calculation is based on the average trading volume of the stock.
Meta Platforms, Inc. (META) is -1.3124 at $615.46, with 2,550,356 shares traded. As reported by Zacks, the current mean recommendation for META is in the "buy range".
Super Micro Computer, Inc. (SMCI) is -0.0697 at $39.52, with 1,937,572 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2026. The consensus EPS forecast is $0.95. SMCI's current last sale is 94.1% of the target price of $42.

After Hours Most Active for Sep 4, 2026 : NIO, INTC, TEVA, AMZN, F, NVDA, XOM, KO, CNH, ABUS, META, SMCI

(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring moves. Ionis, Milestone, Novavax advanced key programs, while United Imaging gained CE Mark for its dual CT systems. Ovid and Vir reported pivotal data, Repligen and Passage Bio expanded deal activity, and TScan and Novartis announced major workforce cuts.
Let's dive into the details...
FDA Approvals
Ionis Pharmaceuticals Inc. (IONS) secured FDA approval for Zanvastro (zilganersen), the first disease-modifying therapy for Alexander disease in adults and children. The antisense drug reduces GFAP protein buildup, with pivotal trial data showing gait speed improvement at 61 weeks. The approval also delivered a Priority Review Voucher, marking Ionis' first independent neurology launch.
IONS closed Thursday's trading (September 3, 2026) at $58.13, down 5.22%.
United Imaging Healthcare Co., Ltd. (UIH) secured European approval for its uCT SiriuX and uCT SiriuX Ultrix systems. Built on a Twin-Ring Gantry architecture, they enable synchronized whole-organ dynamic imaging, ultra-high-resolution spectral scan, expanding advanced diagnostics capabilities across Europe.
UIH closed Friday's trading at $108.58, up 3.33%
Milestone Pharmaceuticals (MIST) gained FDA approval for Etripamil nasal spray, the first self-administered therapy for paroxysmal supraventricular tachycardia (PSVT). The calcium channel blocker showed rapid conversion to normal rhythm in pivotal RAPID and NODE-303 studies, offering patients an at-home option for acute episodes.
MIST closed Thursday's trading at $1.21, up 2.54%
Biogen Inc. (BIIB) and Japan's Eisai Co., Ltd. (ESALY.PK) secured FDA approval for LEQEMBI (lecanemab) as subcutaneous injection for early Alzheimer's disease. The decision, based on Clarity AD trial data showing slowed cognitive decline, expands beyond the IV formulation approved last year. Eisai leads global development, while both companies jointly commercialize the therapy.
BIIB closed Thursday's trading at $224.51, up 0.83%.
AstraZeneca (AZN) and Daiichi Sankyo (DSKYF) won European Commission approval for Enhertu (trastuzumab) in combination with Pertuzumab to treat adult patients with HER2-positive metastatic breast cancer. The decision, backed by Phase 3 DESTINY-Breast09 results showing a 44% risk reduction in disease progression or death versus THP regimen, marks the first new first-line option in over a decade.
AZN closed Thursday's trading at $164.77, up 1.94%
Takeda Pharmaceutical Co., Ltd. (TAK) won FDA approval for Mimrylo (rusfertide) as the first approved therapy for adults with polycythemia vera that mimics hepcidin, a natural iron-regulating hormone. By limiting iron availability, Mimrylo reduces excess red blood cell production, lowering risks of blood clots and cardiovascular complications. The approval was supported by VERIFY trial data, with Takeda pursuing global filing to expand access.
TAK closed Thursday's trading at $18.71, up 1.52%
Novavax, Inc. (NVAX) and partners Sanofi (SNY) and Takeda (TAK) received regulatory approval for the XFG-adapted Nuvaxovid COVID-19 vaccine for the 2026-2027 season in the U.S., EU and Japan. The protein-based shot, developed with recombinant nanoparticles and Matrix-M adjuvant technology, showed favorable tolerability in Sanofi's Phase 4 COMPARE study. Sanofi will lead commercialization in key markets, while Takeda holds exclusive rights in Japan, with Novavax earning royalties on sales.
NVAX closed Thursday's trading at $10.34, up 0.19%.
Layoffs
TScan Therapeutics Inc. (TCRX) announced a strategic restructuring to prioritize its in vivo solid tumor program, advancing two candidates to IND-enabling studies. The company will reduce its workforce by about 75%, eliminate internal manufacturing, and streamline research, targeting $55 million in savings through 2027. Enrollment in the Phase 3 study of TSC-101 has been paused due to capital constraints, though patient follow-up continues.
TCRX closed Thursday's trading at $0.37, down 2.68%
Novartis (NVS) announced plans to transfer biologics production activities from its Kleinbasel site, impacting about 130 positions in Switzerland. The move is part of a broader network reorganization to streamline manufacturing, with the company pledging support for affected employees and continued investment in Swiss operations.
NVS closed Thursday's trading at $163.09, up 0.39%.
Deals
Definitive Healthcare Corp. (DH), a data and analytics company focused on the business side of healthcare, announced that its special committee received a non-binding indication of interest from Advent International L.P. to acquire the company's remaining Class A common shares and Definitive OpCo Units that are not already owned by Advent or Jason Krantz, the company's founder and Executive Chairman, for $1.02 per share/unit in cash.
The committee, composed entirely of disinterested and independent directors, is assessing Advent's proposal and other strategic alternatives, though there can be no assurance that any transaction will be pursued or completed.
DH closed Thursday's trade at $1.04.
Alteogen Inc. (196170.KQ) announced that it has entered into an option and license agreement with Novartis (NVS) under which Novartis will have options to obtain exclusive rights to develop and commercialise subcutaneous formulations for Novartis products using Alteogen's ALT-B4 (berahyaluronidase alfa), a proprietary recombinant human hyaluronidase powered by Alteogen's Hybrozyme technology.
If all options are exercised and all milestones are achieved Alteogen could receive up to $3.223 billion, including option exercise fees, development and commercial milestone payments, and royalties on net sales of products commercialised under the agreement.
NVS closed Thursday's trade at $160.74, down 1.43%.
196170.KQ closed Friday's trade at 288500 Korean Won, up 1.94%.
HUTCHMED China Limited (HCM) announced that its subsidiary has entered into an exclusive development and license agreement with a subsidiary of GSK plc for HMPL-A830, an investigational antibody-targeted therapy conjugate expected to initially enter clinical development in colorectal, pancreatic, and lung cancers.
Under the agreement, HUTCHMED will receive $110 million upfront and is eligible for up to $1.185 billion in development, regulatory, and commercial milestones, bringing the total potential value to $1.295 billion, and GSK's subsidiary will gain worldwide development and commercialisation rights to HMPL-A830, excluding Mainland China, Hong Kong, Macau, and Taiwan. HUTCHMED will retain those rights in the excluded territories.
HCM closed Thursday's trade at $14.11 up 17.19%.
cbdMD, Inc. (YCBD) announced that it has entered into a definitive asset purchase agreement to acquire the operating assets of Twinlab, a supplements and sports nutrition brand, marking a significant step in its expansion into a broader multi-brand consumer wellness platform.
The agreement will add supplement brands to cbdMD's multi-brand consumer wellness platform and is expected to bring combined trailing-12-month revenue to approximately $30 million, representing an increase of roughly 40% compared with cbdMD's standalone revenue illustratively for the same period.
YCBD closed Thursday's trade at $0.48, down 3.76%.
Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced it has entered into an exclusive global licensing agreement with Roche (RHHBY) for the development and commercialisation of SIM0660, a tri-specific antibody designed to address B-cell-mediated diseases.
Under the terms of the agreement, Roche will acquire exclusive worldwide rights to develop, manufacture, and commercialise SIM0660. Simcere Zaiming is eligible to receive up to $1.53 billion in total payments, including $75 million upfront, along with tiered royalties of up to double digits on future net sales.
RHHBY closed Thursday's trade at $55.22, up 2.58%.
BioXcel Therapeutics, Inc. (BTAI) announced that it has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH covering substantially all of BioXcel's assets. Teva will act as the "stalking horse" bidder in a court-supervised Section 363 auction process, establishing a baseline offer intended to maximise value for stakeholders.
The agreement includes BioXcel's IGALMI (dexmedetomidine) sublingual film and the pending supplemental New Drug Application (sNDA) for BXCL501, which seeks approval for potential at-home use in treating agitation associated with schizophrenia or bipolar I or II disorder in adults.
BTAI closed Thursday's trade at $0.11, up 9.81%
Ascendis Pharma A/S (ASND) announced that it has entered into a binding term sheet with BioMarin Pharmaceutical Inc. (BMRN) for a global settlement and license agreement covering YUVIWEL (navepegritide), an approved drug to increase linear growth in pediatric patients aged 2 years and older with achondroplasia and open epiphyses and related products.
Under the settlement, Ascendis will pay BioMarin royalties based on net sales of navepegritide-related products, including 20% in the U.S. and 18% in the European Union, South Korea, and Brazil. The payments will apply from the first commercial sale of YUVIWEL in each country through May 20, 2030.
The agreement resolves all litigation and disputes between the companies and gives Ascendis a non-exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialise navepegritide-related products without restriction.
ASND closed Thursday's trade at $271.12, up 1.43%.
Clinical Trials - Breakthroughs & Setbacks
Aptevo Therapeutics Inc. (APVO) reported a 93% clinical benefit rate with mipletamig, its lead investigational multispecific immuno-oncology therapy, in combination with venetoclax and azacitidine in evaluable patients with frontline acute myeloid leukaemia and TP53 mutations enrolled in the Phase 1b/2 RAINIER study.
According to the company, among 14 evaluable patients with TP53-mutated AML who received the mipletamig triplet, including two patients from a completed dose-expansion trial, 13 patients (93%) experienced clinical benefit. Eleven patients (79%) achieved complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), including nine patients who achieved complete remission.
The RAINIER dose-optimisation phase is expected to be completed by year-end with regulatory discussions planned for the first half of 2027.
APVO closed Thursday's trade at $1.71, down 34.23%.
Ultragenyx Pharmaceutical Inc. (RARE) announced that its Phase 3 Aspire study evaluating Apazunersen(GTX-102), an investigational antisense oligonucleotide therapy in Angelman syndrome, did not meet the primary or key secondary endpoints.
According to the company, the trial did not meet the prespecified primary endpoint of change from Baseline in the Bayley-4 cognitive raw score, nor the key secondary endpoint of net response in the Multidomain Responder Index (MDRI). Following the study outcome, the company said it will review the Apazunersen program and determine the next steps.
RARE closed Thursday's trade at $14.85, down 44.03%
Stoke Therapeutics (STOK) and Biogen (BIIB) announced presentations of long-term data supporting the potential of zorevunersen, an investigational antisense oligonucleotide as a disease-modifying treatment for Dravet syndrome.
The data represent more than 5 years of clinical experience with Zorevunersen in patients with Dravet syndrome, including two Phase 1/2a studies and ongoing open-label extension (OLE) studies.
According to the company, the four-year OLE results showed substantial and durable reductions in seizures and continuing improvements in cognition and behaviour. In addition, a new exploratory sub-analysis also showed substantial reductions in the most severe seizure types, which are strongly associated with morbidity, mortality and sudden unexpected death in epilepsy (SUDEP).
STOK closed Thursday's trade at $29.99, down 1.67%
BIIB closed Thursday's trade at $224.51, up 0.83%.
Teva Pharmaceutical Industries (TEVA) announced that the ongoing Phase 2a study of TEV 408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease met the primary goal.
According to the company, TEV 408 demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8, the study's primary endpoint, with a well-tolerated safety profile.
Results demonstrated favourable effects on biopsy-based measures of intestinal damage, with a least-squares mean change in villous height-to-crypt depth ratio of 0.45 and also reduced inflammation, as intraepithelial lymphocyte density increased by 27.60 in placebo versus 0.37 in TEV-408 participants, a treatment difference of -27.23.
TEVA closed Thursday's trade at $36.62, down 2.32%.
Novartis AG (NVS), a pharmaceutical company, has reportedly paused eight clinical trials evaluating rap-cel, a CD19 CAR-T cell therapy, following the deaths of three patients enrolled in the studies. The deaths may be attributed to a severe immune reaction leading to organ failure, according to The Wall Street Journal.
The trials, which were primarily evaluating the drug for various autoimmune and neurological diseases, were halted on August 24, 2026, after the company was notified about a life-threatening immune reaction among treated patients.
Meanwhile, two trials for rap-cel in treating large B-cell lymphoma (LBCL) and leukaemia are expected to continue.
NVS closed Thursday's trade at $163.09, up 0.39%.
For more biotechstock news visit rttnews.com.

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

The State Street SPDR MSCI EAFE StrategicFactors ETF is seeing unusually high volume in afternoon trading Wednesday, with over 275,000 shares traded versus three month average volume of about 26,000. Shares of QEFA were up about 0.3% on the day.
Components of that ETF with the highest volume on Wednesday were Nebius Group, trading up about 0.8% with over 4.6 million shares changing hands so far this session, and Teva Pharmaceutical Industries, up about 1.9% on volume of over 3.3 million shares. Spotify Technology is the component faring the best Wednesday, up by about 2.6% on the day, while Check Point Software Technologies is lagging other components of the State Street SPDR MSCI EAFE StrategicFactors ETF, trading lower by about 0.7%.

Wednesday's ETF with Unusual Volume: QEFA

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced positive topline results from its ongoing Phase 2a study of TEV-408, an investigational anti-IL-15 monoclonal antibody, in adults with celiac disease.
The study met its primary endpoint, showing statistically significant and clinically meaningful prevention of gluten-induced intestinal damage compared to placebo at Week 8.
Celiac disease is a chronic autoimmune disorder triggered by gluten ingestion, leading to intestinal damage and symptoms such as abdominal pain, diarrhea, and fatigue. While a strict gluten-free diet remains the only available management option, many patients continue to experience persistent symptoms and intestinal injury. TEV-408 is designed to target the IL-15 pathway, a key driver of immune-mediated intestinal damage, offering a potential therapeutic approach beyond dietary restriction.
In the trial, a single subcutaneous dose of TEV-408 was followed by a six-week gluten challenge. Results demonstrated favorable effects on biopsy-based measures of intestinal damage, with a least square mean change in villous height-to-crypt depth ratio of 0.45, 95% CI: (0.06, 0.84), p0.05).
TEV-408 also reduced inflammation, as intraepithelial lymphocyte density increased by 27.60 in placebo versus 0.37 in TEV-408 participants, a treatment difference of -27.23 (95% CI: -39.67, -14.79).
Patient-reported outcomes showed and lower gastrointestinal symptom scores compared to placebo. TEV-408 was well tolerated, with no emerging safety signals observed to date.
Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva, stated that these findings underscore the potential to move beyond managing gluten exposure and address celiac disease at its biological source. He added that the results strengthen confidence in targeting IL-15 as a therapeutic pathway.
The company highlighted that TEV-408 also has potential applications in other immune-mediated conditions, including vitiligo, positioning it as a "pipeline-in-a-product" candidate. Teva will present further data at upcoming scientific meetings and host an investor call to discuss the results.
TEVA has traded between $18.21 and $38.37 over the past year. The stock closed Tuesday's trading at $36.19, up 0.39%. In pre-market trading the stock is at $36.48, up 0.77%.

Teva Reports Positive Phase 2a Results For TEV-408 In Celiac Disease

(RTTNews) - Teva Pharmaceutical Industries (TEVA) announced positive topline results from an ongoing Phase 2a study of TEV 408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease. The study met primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8.
Additional analyses from the ongoing Phase 2a study are underway. The company plans to present further data from the study at a future scientific meeting.
In pre-market trading on NYSE, Teva shares are up 2.96 percent to $37.27.
For More Such Health News, visit rttnews.com.

Teva Pharma Reports Positive Topline Results From Ongoing Phase 2a Study Of TEV 408

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid, while supporting continued investment in scientific innovation and U.S. pharmaceutical manufacturing capabilities.
According to the company, Teva is in active discussions with the Trump Administration regarding an agreement aligned with all four of the President's drug pricing priorities, which include lower U.S. Medicaid prices, Most-Favored-Nation (MFN) pricing for future innovative drugs, U.S. pharmaceutical manufacturing/investment, and strengthening the U.S. pharmaceutical supply chain.
If an agreement is reached, Teva would align U.S. Medicaid pricing for select medicines with leading prices in developed markets under the GENEROUS (GENErating cost Reductions for U.S. Medicaid) framework.
In addition, the agreement would include a prospective Most-Favored-Nation (MFN) commitment for applicable future innovative product launches, the company said. "Teva appreciates the opportunity to work with President Trump and his Administration to expand access and affordability for patients today while enabling continued investment in medicines patients need tomorrow," said Chris Fox, President, Teva USA.
TEVA has traded between $18.14 and $38.37 over the last year. The stock closed Monday's trade at $36.05, down 1.07%.
TEVA is currently up 2.36% at $36.90 in the after-hours market.
For more such biotechstock news visit www.rttnews.com.

Teva Pharma In Talks With Trump Administration On Medicaid Drug Pricing Initiative

Both Neurocrine Biosciences NBIX and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on specialty medicines and treatments for serious health conditions.
NBIX focuses on neuroscience, with growth primarily led by its flagship drug Ingrezza. In contrast, TEVA operates as a global pharmaceutical giant that develops, manufactures and markets both branded and generic/biosimilar drugs.
But which one makes for a better investment pick today? Let's examine the fundamentals of the two stocks to make a prudent choice.
The Case for NBIX
This San Diego-based company’s commercial portfolio currently includes three first-in-class therapies. Neurocrine’s top-line growth is benefiting from strong uptake of Ingrezza, the blockbuster VMAT2 inhibitor approved for two indications — tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD). The drug remains the company’s primary revenue driver and a key pillar of its growth story.
Ingrezza sales rose 17% year over year to $1.4 billion in the first half of 2026, supported by record new prescriptions and double-digit total volume growth. The strong performance prompted management to raise its full-year 2026 Ingrezza sales guidance to $2.83-$2.88 billion from $2.7-$2.8 billion. The midpoint implies approximately 13% year-over-year growth, indicating that Neurocrine expects the drug's commercial momentum to remain solid through the remainder of the year.
The company is also diversifying its revenue base beyond Ingrezza. Crenessity, launched in December 2024 for classic congenital adrenal hyperplasia (CAH), is emerging as a meaningful second growth driver. The drug generated $337 million in sales in the first half of 2026, up about 400% year over year and already exceeding its full-year 2025 sales of $301 million.
The company further expanded its rare-disease portfolio through the $2.9 billion acquisition of Soleno Therapeutics, completed in May 2026. The acquisition added Vykat XR, which is approved to treat hyperphagia in Prader-Willi syndrome (PWS). Following the acquisition, Neurocrine recorded $54 million from the drug’s sales in the second quarter of 2026.
Beyond its marketed products, Neurocrine has a broad pipeline. Its late-stage pipeline includes phase III programs for osavampator in major depressive disorder and direclidine in schizophrenia. The company also has several earlier-stage programs targeting areas including obesity, classic CAH and movement disorders. NBIX expects around 10 clinical study readouts next year.
However, Ingrezza remains a major source of revenues, leaving Neurocrine exposed to competitive pressures. Teva's Austedo and Austedo XR compete directly with Ingrezza in TD and HD chorea. In addition, pricing pressure could increase as a lower negotiated Medicare price for Austedo takes effect in 2027.
Neurocrine is also facing execution risks with Vykat XR, which remains in the early stages of commercialization. Post-marketing serious adverse events have been reported to the FDA, although such reports do not establish that the drug caused the events. NBIX acknowledges that adverse-event or safety concerns could affect market acceptance, prompt regulatory scrutiny or increase treatment discontinuations.
The Case for TEVA
The Israel-based company is one of the world’s largest generic drugmakers in terms of both total and new prescriptions. It enjoys a leading position in the United States, where it commands a share of more than 6% of total U.S. generic prescriptions.
Teva is gradually moving from predominantly traditional small-molecule generic manufacturer to a more diversified player in complex generics and biosimilars. In the past few quarters, the company has launched several successful biosimilars and other high-value complex generics. These include Truxima (biosimilar to Roche’s Rituxan), Simlandi (biosimilar to AbbVie’s Humira), Selarsdi (biosimilar to J&J’s Stelara), Epysqli (biosimilar to AstraZeneca’s Soliris) and Novo Nordisk’s Victoza.
Teva also maintains a diversified portfolio of higher-margin branded and innovative medicines, which are transforming its portfolio mix and financial profile. Its newer products — Austedo, Ajovy (preventive treatment of migraine) and Uzedy (schizophrenia) — are gaining market share and delivering strong top-line growth.
Austedo remains the largest contributor to the franchise, with global sales rising 40% year over year to $696 million in the second quarter. Teva expects Austedo revenues of $2.45-$2.60 billion in 2026. The Austedo franchise got a boost from the launch of Austedo XR, a new once-daily formulation of Austedo. Teva expects Austedo revenues to exceed $3 billion by 2030.
Ajovy is also delivering strong growth, with global revenues increasing 56% year over year to $244 million in the second quarter. Teva expects Ajovy sales of $850-$870 million in 2026 and estimates peak global sales potential of approximately $1 billion. Meanwhile, Uzedy revenues increased 43% to $77 million in the second quarter, with full-year 2026 sales expected to reach $270-$290 million.
However, Teva’s generics business faces a revenue cliff for lenalidomide capsules (the generic version of Bristol-Myers’ Revlimid), due to increased competition in the United States. Global generics revenues are expected to be flat to down in the low single digits in local currency in 2026, excluding the impact of generic Revlimid and the Japan business divestment. This outlook reflects fewer high-value launches, lower seasonal demand for OTC products and increased competition in some markets. The generic market is also highly crowded, as Teva competes with players like Dr. Reddy’s RDY, Viatris and Sandoz, among others.
The company also faces competitive pressure for some of its key branded drugs. Austedo competes with Ingrezza, while Ajovy faces competition from other CGRP-targeting therapies, including Amgen's Aimovig and Eli Lilly's LLY Emgality.
In addition, Teva has a high debt load – the company’s consolidated debt (short- plus long-term) was approximately $16.6 billion at the end of June 2026.
How Do Estimates Compare for NBIX & TEVA?
The Zacks Consensus Estimate for Neurocrine’s 2026 sales and EPS implies year-over-year growth of 31% and 27%, respectively. Bottom-line estimates for 2026 have declined during the past 30 days.
For Teva, the Zacks Consensus Estimate for 2026 sales is expected to decline 4% year over year, while EPS estimates are expected to fall 6%. Bottom-line estimates for 2026 have been trending downwards over the past 30 days.
Price Performance and Valuation of NBIX & TEVA
Year to date, shares of Neurocrine have risen 8%, while those of TEVA have increased 18%. In comparison, the industry has climbed 2%, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, NBIX seems to be trading at a premium compared to TEVA, going by the price/earnings (P/E) ratio. Neurocrine’s shares currently trade at 17.61 times forward 12-month earnings, higher than 13.91 for Teva.
Image Source: Zacks Investment Research
NBIX or TEVA: Which Is a Better Pick?
Both Neurocrine and Teva offer investors exposure to growing neuroscience markets and both have important commercial products that could support future growth. However, NBIX appears to be the better pick at present.
Neurocrine offers a stronger near-term growth trajectory, supported by continued Ingrezza momentum, the rapid growth of Crenessity and the addition of Vykat XR. The company also has a broader pipeline, with multiple potential clinical readouts expected in 2027, providing several catalysts that could support the stock’s performance.
In comparison, Teva’s innovative medicines, particularly Austedo, Ajovy and Uzedy, are delivering strong growth. However, weakness in its generics business remains a near-term headwind, while the company’s high debt load adds to its financial risk. These factors could limit the upside potential of the stock despite the strength of its newer branded medicines.
NBIX carries a Zacks Rank #3 (Hold), while TEVA has a Zacks Rank #4 (Sell). This further reinforces NBIX’s more favorable standing in the current investment landscape.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

Neurocrine Biosciences NBIX delivered a better-than-expected second quarter, with revenues and adjusted earnings per share topping the Zacks Consensus Estimate. The company also raised its 2026 Ingrezza sales outlook, reinforcing the role of its flagship therapy in near-term growth.
The next test is whether prescription momentum, Crenessity's launch and Vykat XR can keep widening the revenue base as research and commercial spending rises. That balance matters because Ingrezza remains Neurocrine's main revenue engine even as newer products broaden the portfolio.
NBIX Delivers a Strong Q2 Beat
Second-quarter revenues increased 39% year over year to $959 million, above the Zacks Consensus Estimate of $901.5 million. Adjusted earnings of $2.85 per share rose 73% and beat the consensus estimate of $2.26.
The beat was broad-based. Ingrezza sales reached $716 million versus the $628.6 million consensus mark, while Crenessity generated $184 million compared with the $170.8 million estimate. Vykat XR added $54 million from May 18 through quarter-end, giving Neurocrine contributions from all three marketed therapies.
Neurocrine Raises the Bar for Ingrezza
Ingrezza sales increased 15% in the second quarter and 17% in the first half of 2026 to $1.4 billion. Neurocrine cited double-digit prescription volume growth, record new prescriptions and continued access covering about 70% of Medicare lives.
Management raised 2026 Ingrezza net product sales guidance to $2.825-$2.875 billion from $2.7-$2.8 billion, implying roughly 13% growth at the midpoint. Neurocrine estimates that tardive dyskinesia affects about 800,000 U.S. patients, with roughly 10% receiving a VMAT2 inhibitor. Teva Pharmaceutical Industries Ltd. TEVA markets competing Austedo and Austedo XR in tardive dyskinesia and Huntington's disease chorea.
Neurocrine Biosciences, Inc. Price and EPS Surprise
NBIX Adds Rare-Disease Growth Engines
Crenessity generated $337 million in first-half 2026 sales, up about 400% year over year and already above its $301 million total for 2025. About 15% of the estimated diagnosed classic congenital adrenal hyperplasia population has been prescribed the drug, and its prescriber base has nearly tripled.
Vykat XR contributed $54 million in reported second-quarter sales after the Soleno acquisition closed in May, while unaudited pro forma full-quarter sales were $94 million. Neurocrine expects launch-related discontinuations to largely work through during the third quarter and anticipates sequential sales growth beginning in the fourth quarter.
Neurocrine Is Spending More To Scale
Adjusted research and development expenses rose 24% to $276.1 million, reflecting investment across a broader development portfolio. Adjusted selling, general and administrative expenses increased 20% to $304.9 million as Neurocrine expanded commercial support for Ingrezza, Crenessity and Vykat XR.
The company also raised 2026 adjusted research and development guidance to $1.14-$1.19 billion and selling, general and administrative guidance to $1.325-$1.35 billion. Bristol Myers Squibb BMY already markets Cobenfy for adults with schizophrenia, a market relevant to Neurocrine's phase III direclidine program and its expanding research investment.
NBIX Signals Temper Q2 Optimism
The second-quarter beat, higher Ingrezza guidance and growing rare-disease portfolio support the revenue story, but higher operating investment and execution risks keep the outlook balanced. Vykat XR retention, Ingrezza pricing exposure and pipeline delivery remain important variables as Neurocrine scales.
NBIX currently carries a Zacks Rank #3 (Hold), which is less favorable than the #1 and 2 (Buy) ranks that Zacks Style Scores are designed to complement most effectively. Its Growth Score of A and VGM Score of A indicate favorable growth and blended style characteristics, while its Value Score of B is also constructive. The Momentum Score of D points to weaker momentum characteristics, tempering the otherwise favorable Style Score mix.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Periodand min./max. price, $	Price change, %		Volatility, %		Volume, $
Periodand min./max. price, $	TEVA	Industry	TEVA	Industry	Volume, $
Yesterday 36.1 - 37.1	-2.30	6.30	8.89	1.12	79.65M
Week 35.4 - 37.3	-2.14	5.01	5.96	2.57	509.25M
Month 35.4 - 38.4	-3.46	10.30	11.15	6.55	2.71B
3 Months 29.6 - 38.4	2.33	7.33	25.86	11.53	8.28B
6 Months 27.9 - 38.4	21.25	27.56	29.04	20.25	16.97B
Year 18.2 - 38.4	80.09	27.75	39.54	37.72	44.34B
3 years 8.1 - 38.4	254.45	35.27	71.55	70.17	107.34B
5 years 6.8 - 38.4	284.68	86.63	95.90	96.88	148.31B
All time 5.8 - 72.3	187.24	100.65	—	—	115.03B

Teva Pharmaceutical Industries Limited

Price and volatility history

Risk ratios